Skip to main content

Abstract Submission FAQs and Guidelines - December 2023 Virtual Conference

Abstract submission is closed. Notification emails for oral presentations have been sent. If you have any questions, please contact This email address is being protected from spambots. You need JavaScript enabled to view it..
Following is a list of the abstracts that were selected for oral presentation:
  • #503 - Visualizing 3-year treatment outcome trajectories of dupilumab in adults with moderate-to-severe atopic dermatitis in real world practice
  • #517 - Lebrikizumab demonstrates significant efficacy versus placebo across racial and ethnic subgroups in patients with moderate-to-severe atopic dermatitis
  • #518 - Interaction of sleep disturbance and nocturnal scratch in atopic dermatitis patients
  • #520 - Evaluating the expression of OX40 and OX40 ligand in lesional skin versus non-lesional skin in volunteers with atopic dermatitis and in healthy control skin
  • #525 - Real-world effectiveness of upadacitinib in moderate-to-severe atopic dermatitis (AD): Results from cross-sectional analyses of the CorEvitas AD Registry
  • #529 - Worsening of itch before flaring in patients with moderate-to-severe atopic dermatitis treated with abrocitinib: a post hoc analysis of the phase 3 JADE REGIMEN trial
  • #531 - Physician-Assessed Effectiveness and Patient-Reported Outcomes in Adult and Adolescent Atopic Dermatitis Patients Treated with Dupilumab: Real-World Insights One Year into the GLOBOSTAD Multinational Prospective Observational Study
  • #533 - Long-term 5-year safety of upadacitinib in moderate-to-severe atopic dermatitis: An integrated analysis including over 7000 patient-years of exposure
  • #534 - Incidence of venous thromboembolic events and atherosclerotic cardiovascular disease risk factors in adolescents and adults with atopic dermatitis in Denmark: a population-based cohort study
  • #541 - Real-world effectiveness of dupilumab in adult and adolescent patients with atopic dermatitis: 3-year data from the PROSE registry
  • #564 - Conjunctivitis adverse events in dupilumab clinical trials
  • #568 - Persistent Inadequate Disease Control and Therapeutic Inertia in Moderate-to-Severe Atopic Dermatitis: A 12-month Longitudinal Analysis of Real-world Outcomes from TARGET-DERM registry

Important Dates

Abstract Submission
Opens Saturday, July 1, 2023

Abstract Submission Deadline
Friday, November 3, 2023 (11:59 PM EST)

Abstract Acceptance Notifications
Rolling - notifications will be emailed to the submitter's email address within approximately 1 week of abstract submission

Late Breaker Submission Deadline
Friday, November 10, 2023 (5:00 PM EST)

Oral Acceptance Notifications (See below for additional requirements if accepted for an Oral Presentation)*
Notification: Week of November 20, 2023

Final Poster and Abstract for Electronic Posting
Friday, December 1, 2023 (11:59 PM EST)

Important Information Regarding Oral Presentations*

Please be aware of the following dates and requirements in the event you are selected:

A list of abstracts that have been accepted as oral presentations will be posted on the Conference Agenda one week prior to the conference.

  • *Monday, November 27, 2023 (11:59 PM EST) - Presentations must be submitted for CME approval. Format will be PPT. There will be no extensions. More details to follow upon acceptance.
  • Frequently Asked Questions (FAQs)

    Is there an abstract submission fee?
    Yes - US $125.00

    Are there rules about previous presentations and adaptations of data at conferences and in publications?
    Encore and adapted presentations are permitted. All abstracts will undergo review by the Abstract Review Committee who will assess for scientific merit and novelty. The submitting author must provide the name of the conference/publication, presentation/publication date and presentation venue.

    Is a trial-in-progress abstract allowed?

    Is there an author limit for abstracts?

    Is there a word limit or character count to which we should adhere?
    600 words; 1 chart or graph is allowed (word count does not include title, authors, author affiliations, references or disclosures)

    May a non-author present on behalf of the authors?

    • Yes, for non-accredited poster presentations
    • No, for accredited poster or oral presentations

    May an industry employee present on behalf of the authors?

    • Yes, for non-accredited poster presentations
    • No, for accredited poster or oral presentations

    Is Industry Sponsorship allowed?

    Is Society Sponsorship required for admission?

    Are QR codes allowed on the posters?

    Do you have any policy regarding the usage of brand names or trademarks in abstracts or posters?
    Brand names or trademarks are NOT allowed - only generic names may be used.

    Will you accept an abstract presenting only the study design?
    It would be preferable if the abstract included the results/read outs; however, if they are not available at the time of submission but will be presented at the conference, that would be acceptable.

    What are the Embargo Rules, if any?

    • None for encore presentations
    • For primary disclosures, scientific dissemination must be reserved until after presentation at the conference. Press releases and media coverage are allowed in advance of the conference provided that data is not included.

    Where will the abstracts be published?
    All accepted abstracts will be published in the British Journal of Dermatology (BJD) as well as on the RAD Website.

    What is the pre-conference abstract availability date/access venue?
    Saturday, December 9, 2023 - 7:00 PM (EST)

    What is the post-conference abstract availability date/access venue?
    In perpetuity

    Is there a language requirement for the abstracts?

    Abstract Guidelines and Format

    As you prepare your submission to the conference, please make note of the following details:

    • All types of atopic dermatitis related research are eligible for submission.
    • Abstract should address scientific questions, detail clinical observations, or contain primary scientific data.
    • Encore presentations of data from previously presented research may be submitted.
    • Abstracts must be submitted in Word format only.
    • Abstracts must be submitted in English only.


    • Please ensure that you include the title, author information including first and last name (middle initial if available), and author institution (name, city, state/province, and country)
    • Titles to be in bold, sentence case
    • Affiliations to be designated with superscript numbers
    • Please include all sections indicated in the Abstract Template
    • Please double-space
    • Word Limit: 600 Words (word count does not include title, authors, author affiliations, references or disclosures)
    • You may insert one (1) chart or graph. (Note: charts and graphs will be included on the RAD Website; however, they will not be included in the British Journal of Dermatology
    Please click below to view the Abstract Template. Abstract format must follow the template provided.

    Guidelines for Posters

    The following should be completed by Friday, December 1, 2023, at 11:59 PM (EST) and uploaded via the link that will be provided in your acceptance email:

    1. A digital presentation of your poster in high-resolution PDF format must be provided.
      1. Posters may be formatted as:
        1. A conventional poster on a single slide to fit on a 16 x 9 PPT slide
    2. You may also submit an optional 3-minute video presentation of your poster that will be included on the RAD website. Video presentations should be provided in MP4 format.
      1. The presenter should not be an employee of an industry sponsor.
    3. Posters/presentations generated by ChatGPT or other artificial intelligence software will not be accepted.

      Guidelines for Oral Presentation Authors Should You be Accepted

      You will receive notification the week of November 20 if your abstract has been accepted to be presented as an oral presentation. The following will be required to present during the virtual conference. Upon acceptance, you will be assigned a presentation time. Please see below for further details.

      Please note: Presentations generated by ChatGPT or other artificial intelligence software will not be accepted.

      The presenting author must:

      • Agree to the Confidentiality Policy on behalf of all parties involved with the abstract and communicate this policy to all involved parties. The Confidentiality Policy applies to both standard and late-breaking data submission from the time of abstract submission.
      • You will need to provide your oral presentation slides and disclosure information for CME approval by Monday, November 27, 2023.
        • Oral presentations will be 5-7 minutes.
      • Verify that, if necessary for the work reported, the clinical research represented in the abstract was approved by an appropriate ethics committee or institutional review board and that, if appropriate to the research, informed consent was obtained for all subjects.
      • Verify that all coauthors are aware of the contents of the abstract and support its data.
      • Agree, on behalf of all coauthors, to publication of the abstract in the final scientific program.
      • For an abstract to be included in the final scientific program, it is mandatory for the presenting author to register for the conference and to settle payment within 72 hours of receiving the abstract acceptance. If accepted, you will receive a discount code via your oral presentation acceptance notification email.
      • Agree to present the abstract if it is selected for oral presentation at the RAD Virtual Conference. This includes being present during the scheduled time of the oral session.
      • Agree to list all potential conflicts of interest in the presentation if the abstract is accepted for oral presentation at the RAD Conference.
      • Ensure that all coauthors meet the definition of authorship as stated by the International Committee of Medical Journal Editors.
      • Enter the name of the clinical trial registry and the trial.
      If you have any questions or need additional information, please contact This email address is being protected from spambots. You need JavaScript enabled to view it..